| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | — | — | — | — | 7.66 | 0.16 |
| Quick Ratio | — | — | — | — | 7.66 | 0.16 |
| Debt / Equity | — | — | — | — | 0.00 | -0.18 |
| ROE | -121.45% | -787.11% | -122.65% | -159.60% | -78.19% | 101.84% |
| ROA | -96.12% | -347.70% | -97.69% | -138.40% | -67.98% | -534.56% |
| Asset Turnover | — | — | — | — | — | — |
| Book Value / Share | 6.72 | 1.02 | 32.60 | — | 2.35 | -1.66 |
Dermata Therapeutics Inc. is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for medical skin diseases and aesthetic applications. Its lead product candidate, XYNGARI, is in Phase 3 clinical studies for moderate-to-severe acne and has completed Phase 1b proof-of-concept trials for mild-to-moderate psoriasis. The company is also advancing DMT410, which has completed Phase 1b proof-of-concept trials for axillary hyperhidrosis and aesthetic skin conditions, utilizing its proprietary Spongilla technology platform for intradermal delivery, including topical botulinum toxin. Dermata Therapeutics Inc. leverages this technology across dermatologic treatments for conditions like acne, psoriasis, rosacea, and seborrheic dermatitis, aiming to deliver innovative once-weekly topical therapies. It maintains clinical trial collaborations to evaluate combinations such as XYNGARI with botulinum toxin products. Founded in 2014 and headquartered in San Diego, California, Dermata Therapeutics Inc. plays a key role in advancing targeted dermatology solutions in the biotechnology sector.